.jpg?format=webp&quality=80&width=3840)
A study revealed that COPD is prevalent among heart failure patients with mildly reduced or preserved ejection fractions (HFmrEF/HFpEF) and is linked to poorer outcomes. They found that patients with mild-to-moderate COPD faced a higher risk of cardiovascular death or worsening HF. However, the diabetes drug dapagliflozin showed consistent benefits in reducing these risks across all COPD statuses. This suggests dapagliflozin could be a valuable addition to HFmrEF/HFpEF treatment, regardless of COPD presence.
Like
Save
Share